Paraplegia following intrathecal cytosine arabinoside.
Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days. Cerebrospinal fluid examination prior to the last dosage of cytosine arabinoside revealed a mononuclear pleocytosis and increased protein. The neurological manifestations developed within one week after the last dose of Ara-C and persisted for over 8 weeks. Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (paresthesias) in only one of 30 patients so treated.
D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects* / Q000134:cerebrospinal fluid; D006801:Humans; D007278:Injections, Spinal; D015470:Leukemia, Myeloid, Acute / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008297:Male; D010264:Paraplegia / Q000139:chemically induced*
D003561:Cytarabine